Lung cancer is the third most common malignancy and still the leading cause of cancer death in the world. In the United States, it is projected that there may be approximately 222,500 new cases and 155,870 deaths from lung cancer in 2017.¹ The development of target agents and immunotherapy has improved treatment outcomes, but ultimate resistance to these therapies requires new approaches to combat carcinogenesis and resistance to current therapies.²

中文翻译：

---

新型亮氨酰-tRNA合成酶抑制剂BC-LI-0186对非小细胞肺癌的治疗作用

肺癌是第三大最常见的恶性肿瘤，仍然是世界上癌症死亡的主要原因。在美国，预计 2017 年可能有大约 222,500 例新病例和 155,870 例肺癌死亡^。1靶向药物和免疫疗法的开发改善了治疗结果，但对这些疗法的最终耐药性需要新的方法来对抗致癌作用以及对当前疗法的抵抗力。²